

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Sheet

1

of

9

<i>Complete if Known</i>	
Application No.	10/577,742
Filing Date	July 19, 2006
First Named Inventor	Brett B. Finlay
Art Unit	1645
Examiner Name	Oluwatosin A. Ogunbiyi
Attorney Docket Number	27112-14589

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document No.	Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
	A1	US-6,730,822	05-04-2004	Ivarie et al.
	A2	US-6,365,723	04-02-2002	Blattner et al.
	A3	US-6,165,743	12-26-2000	Rambach
	A4	US-6,136,554	10-24-2000	Bochner
	A5	US-5,951,988	09-14-1999	Little-van den Hurk et al.
	A6	US-5,750,113	05-12-1998	Cook
	A7	US-5,151,267	09-29-1992	Babiuk et al.
	A8	US-4,744,984	05-17-1988	Ragland
	A9	US-4,708,871	11-24-1987	Geysen
	A10	US-4,310,550	01-12-1982	Wolff, III et al
	A11	US-2002/0173478 A1	11-21-2002	Gewirtz
	A12	US-2002/0132788 A1	09-19-2002	Lewis et al.

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T <sup>6</sup>
	B1	JP2002355074 A2 (English Abstract)	12-10-2002	University Tsukuba	
	B2	WO 97/40063	10-30-1997	Finlay et al.	
	B3	WO 99/24576	05-20-1999	Finlay et al.	
	B4	WO 02/053181	07-11-2002	Finlay et al.	
	B5	WO 05/042746 A1	05-12-2005	Finlay et al.	

**OTHER REFERENCES – NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>6</sup>
	C1	FELGNER, PHILIP L., "Particulate systems and polymers for in vitro and in vivo delivery of polynucleotides," Advanced Drug Delivery Reviews, 1990, 5(3), pages 163-187.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Sheet

2

of

9

<b>Complete if Known</b>	
<b>Application No.</b>	10/577,742
<b>Filing Date</b>	July 19, 2006
<b>First Named Inventor</b>	Brett B. Finlay
<b>Art Unit</b>	1645
<b>Examiner Name</b>	Oluwatosin A. Ogunbiyi
<b>Attorney Docket Number</b>	27112-14589

**OTHER REFERENCES – NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>6</sup>
	C2	VAN DALEN, F., et al., "Preparation and Characterization of Liposomes with Incorporated Neisseria gonorrhoeae Protein IB and Amphiphilic Adjuvants," Journal of Controlled Release, 1988, Pages 123-132, Vol. 7.	
	C3	PRAGER, M., "Kodak Laboratory Chemicals Bulletin, 1986, 56(1), Page 1-5.	
	C4	ABE, A. et al., "Enteropathogenic Escherichia coli traslocated intimin receptor, Tir, requires a specific chaperone for stable secretion," Mol. Microbiol., 1999, 33(6), Page 1162-1175.	
	C5	ABE, A. et al., "Two enteropathogenic Escherichia coli, type III secreted proteins, EspA and EspB, are virulence factors," Journal of Experimental Medicine, 1998, 188, pages 1907-1916.	
	C6	ALTSCHUL, S.F., "Amino acid substitution matrices from an information theoretic perspective," Journal of Molecular Biology, 1991, 219, pages 555-665.	
	C7	ALYMOVA, IV et al., "Immunogenicity and protective efficacy in mice of influenza B virus vaccines grown in mammalian cells or embryonated chicken eggs," J. Virol., 1998, Vol. 72, No. 5, Pages 4472-4477.	
	C8	BABIUK et al., "Protection of Cattle from Bovine Herpesvirus Type I (BHV-1) Infection by Immunization with Individual Viral Glycoproteins," Virology, 1986, Vol. 159, Pages 57-66.	
	C9	BEUZON, C.R. et al., "Use of mixed infections with Salmonella strains to study virulence genes and their interactions in vivo," Microbes and Infection, 2001, Vol. 3, Pages 1345-1352.	
	C10	BROWN, D., et al., "RNA Interference in Mammalian Cell Culture: Design, Execution and Analysis of the siRNA Effect," Ambion, The RNA Company, [online] retrieved from the internet on 09/26/07, 7 pages, Retrieved from Biocompare, The Buyer's Guide for Life Scientists, Technical Articles.	
	C11	BRUNDER, W., et al., "EspP, a novel extracellular serine protease of enterohaemorrhagic Escherichia coli O157:H7 cleaves human coagulation factor V," Molecular Microbiology, 1997, pgs. 767-778, Vol. 24, No. 4.	
	C12	BUCHET, A., et al., "Positive co-regulation of the Escherichia coli carnitine pathway cai and fix operons by CRP and the CaiF activator," Molecular Microbiology, 1999, pgs. 562-575, Vol. 34, No. 3.	
	C13	BUCHRIESER, C., et al., "The virulence plasmid pWR100 and the repertoire of proteins secreted by the type III secretion apparatus of <i>Shigella flexneri</i> ," Molecular Microbiology, 2000, pgs. 760-771, Vol. 38(4).	
	C14	BUSTAMANTE, V. H., et al., "Transcriptional regulation of type III secretion genes in enteropathogenic Escherichia coli: Ler antagonizes H-NS-dependent repression," Molecular Microbiology, 2001, pgs. 664-678, Vol. 39, No. 3.	
	C15	CANIL, C., et al., "Enteropathogenic Escherichia coli Decreases the Transepithelial Electrical Resistance of Polarized Epithelial Monolayers," Infection and Immunity, July 1993, pgs. 2755-2762, Vol. 61, No. 7.	
	C16	CELLI, J., et al., "Enteropathogenic Escherichia coli mediates antiphagocytosis through the inhibition of PI 3-kinase-dependent pathways," The EMBO Journal, 2001, pgs. 1245-1258, Vol. 20, No. 6.	
	C17	CHARDIN, P., et al., "Brefeldin A: The Advantage of Being Uncompetitive," Cell, April 16, 1999, pgs. 153-155, Vol. 97.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Sheet

3 of 9

<b>Complete if Known</b>	
<b>Application No.</b>	10/577,742
<b>Filing Date</b>	July 19, 2006
<b>First Named Inventor</b>	Brett B. Finlay
<b>Art Unit</b>	1645
<b>Examiner Name</b>	Oluwatosin A. Ogunbiyi
<b>Attorney Docket Number</b>	27112-14589

**OTHER REFERENCES – NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>6</sup>
	C18	CHERNUSHEVICH, I. V., et al., "An introduction to quadrupole -- time-of-flight mass spectrometry," <i>Journal of Mass Spectrometry</i> , 2001, pgs. 849-865, Vol. 36.	
	C19	Clin. Exp. Immunol., 1989, 78(2), 256-262	
	C20	CORNELIS, G. R., "Yersinia type III secretion: send in the effectors," <i>The Journal of Cell Biology</i> , August 5, 2002, pgs. 401-408, Vol. 158, No. 3.	
	C21	DAYHOFF, M.O. et al., "A model of evolutionary change in proteins," <i>Atlas of Protein Sequence and Structure</i> , Dayhoff, M.O. (ed.), 1978, 5(3), Pages 345-352, National Biomedical Research Foundation, Washington.	
	C22	DENG, W. et al., "Citrobacter rodentium translocated intimin receptor (Tir) is an essential virulence factor needed for actin condensation, intestinal colonization and colonic hyperplasia in mice," <i>Mol. Microbiol.</i> , 2003, 48, pages 95-115.	
	C23	DENG, W. et al., "Dissecting virulence: Systematic and functional analyses of a pathogenicity island," <i>PNAS</i> , March 2004, 101(10), pages 3597-3602.	
	C24	DENG, W. et al., "Locus of enterocyte effacement form Citrobacter rodentium: sequence analysis and evidence for horizontal transfer among attaching and effacing pathogens," <i>Infect. Immun.</i> , 2001, 69(10), pages 6323-6335.	
	C25	DEVINNEY, R. et al., "Enterohemorrhagic Escherichia coli O157:H7 produces Tir, which is translocated to the host cell membrane but is not tyrosine phosphorylated," <i>Infect. Immun.</i> , 1999, 67(5), pages 2389-2398.	
	C26	DONNENBERG, M.S. et al., "Construction of an eae deletion mutant of enteropathogenic Escherichia coli by using a positive-selection suicide vector," <i>Infect. Immun.</i> , 1991, 59(12), pages 4310-4317.	
	C27	EDWARDS, R.A. et al., "Improved allelic exchange vectors and their use to analyze 987P fimbria gene expression," <i>Gene</i> , 1998, 207, pages 149-157.	
	C28	ESIGNBERG, D. et al., "Analysis of membrane and surface protein sequences with the hydrophobic moment plot", <i>J. Mol. Bio.</i> , 1984 Oct. 15, 179(1), pages 125-142, 184.	
	C29	ELDER, R.O. et al., "Correlation of enterohemorrhagic Escherichia coli O157 prevalence in feces, hides, and carcasses of beef cattle during processing", <i>Proc. Natl. Acad. Sci. USA</i> , March 28, 2000, 97(7), pages 2999-3003.	
	C30	ELLIOT, S. J., et al., "Identification of CesT, a chaperone for the type III secretion of Tir in enteropathogenic <i>Escherichia coli</i> ," <i>Molecular Microbiology</i> , 1999, pgs. 1176-1189, Vol. 33, No. 6.	
	C31	ELLIOT, S. J., et al., "EspG, a Novel Type III System-Secreted Protein from Enteropathogenic <i>Escherichia coli</i> with Similarities to VirA of <i>Shigella flexneri</i> ," <i>Infection and Immunity</i> , June 2001, pgs. 4027-4033, Vol. 69, No. 6.	
	C32	ELLIOT, S. J., et al., "The complete sequence of the locus of enterocyte effacement (LEE) from enteropathogenic <i>Escherichia coli</i> E2348/69," <i>Molecular Microbiology</i> , 1998, pgs. 1-4, Vol. 28, No. 1.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Sheet

4 of 9

<b>Complete if Known</b>	
<b>Application No.</b>	10/577,742
<b>Filing Date</b>	July 19, 2006
<b>First Named Inventor</b>	Brett B. Finlay
<b>Art Unit</b>	1645
<b>Examiner Name</b>	Oluwatosin A. Ogunbiyi
<b>Attorney Docket Number</b>	27112-14589

**OTHER REFERENCES – NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>6</sup>
	C33	FEY, P. D., et al., "Prevalence of Non-O157:PH7 Shiga Toxin-Producing <i>Escherichia coli</i> in Diarrheal Stool Samples from Nebraska," <i>Emerging Infectious Diseases</i> , September-October 2000, pgs. 530-533, Vol. 6, No. 5.	
	C34	FRANKEL, G., et al., Enteropathogenic and enterohaemorrhagic <i>Escherichia coli</i> : more subversive elements," <i>Molecular Microbiology</i> , 1998, pgs. 911-921, Vol. 30, No. 5.	
	C35	GALÁN, J. E., "Salmonella Interactions with Host Cells: Type III Secretion at Work," <i>Annual Review of Cell Developmental Biology</i> , 2001, pgs. 53-86, Vol. 17.	
	C36	GALL, D., "The Adjuvant Activity of Aliphatic Nitrogenous Bases," <i>Immunology</i> , 1996, pgs. 369-386, Vol. 11.	
	C37	GAUTHIER, A., et al., "Mechanical Fractionation Reveals Structural Requirements for Enteropathogenic <i>Escherichia coli</i> Tir Insertion into Host Membranes," <i>Infection and Immunity</i> , July 2000, pgs. 4344-4348, Vol. 68, No. 7.	
	C38	GOOSNEY, D. L., et al., "Recruitment of Cytoskeletal and Signaling Proteins to Enteropathogenic and Enterohemorrhagic <i>Escherichia coli</i> pedestals," <i>Infection and Immunity</i> , May 2001, pgs. 3315-3322, Vol. 69, No. 5.	
	C39	GRIFFIN, P. M., et al., "Illness Associated with <i>Escherichia coli</i> 0157:H7 Infections," <i>Annals of Internal Medicine</i> , November 1988, pgs. 705-712, Vol. 109.	
	C40	GRUENHEID, S., et al., "Enteropathogenic <i>E. coli</i> Tir binds Nck to initiate actin pedestal formation in host cells," <i>Nature Cell Biology</i> , September 2001, pgs. 856-859, Vol. 3.	
	C41	GRUENHEID, S., et al., "Identification and characterization of NleA, a non-LEE-encoded type III translocated virulence factor of enterohaemorrhagic <i>Escherichia coli</i> O157:H7," <i>Molecular Microbiology</i> , 2004, pgs. 1233-1249, Vol. 51, No. 5.	
	C42	GRUENHEID, S., et al., "Microbial pathogenesis and cytoskeletal function," <i>Nature</i> , 2003, pgs. 775-781, Vol. 422.	
	C43	GUTTMAN, D. S., et al., "A Functional Screen for the Type III (Hrp) Secretome of the Plant Pathogen <i>Pseudomonas syringae</i> ," <i>Science</i> , March 1, 2002, pgs. 1722-1726, Vol. 295.	
	C44	HACKER, J., et al. "Pathogenicity Islands and the Evolution of Microbes," <i>Annual Review Microbiology</i> , 2000, pgs. 641-679, Vol. 54.	
	C45	HAMMOND, S. M., et al., "Post-Transcriptional Gene Silencing by Double-Stranded RNA," <i>Nature Reviews, Genetics</i> , February 2001, pgs. 110-119, Vol. 2.	
	C46	HAUF, N., et al., "Suppression of NF-κB Activation and Proinflammatory Cytokine Expression by Shiga Toxin-Producing <i>Escherichia coli</i> ," <i>The Journal of Immunology</i> , 2003, pgs. 2074-2082, Vol. 170.	
	C47	HENIKOFF, S., et al., "Performance Evaluation of Amino Acid Substitution Matrices," <i>Proteins: Structure, Function and Genetics</i> , 1993, pgs. 49-61, Vol. 17.	
	C48	HENIKOFF, S., et al., "Amino acid substitution matrices from protein blocks," <i>Proceedings of the National</i>	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Sheet

5 of 9

<b>Complete if Known</b>	
<b>Application No.</b>	10/577,742
<b>Filing Date</b>	July 19, 2006
<b>First Named Inventor</b>	Brett B. Finlay
<b>Art Unit</b>	1645
<b>Examiner Name</b>	Oluwatosin A. Ogunbiyi
<b>Attorney Docket Number</b>	27112-14589

**OTHER REFERENCES – NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>6</sup>
		Academy of Sciences USA, Biochemistry, November 1992, pgs. 10915-10919, Vol. 89.	
	C49	HOUTHAEVE, T. et al., "Automation of micro-preparation and enzymatic cleavage of gel electrophoretically separated proteins", FEBS Lett., 1995, 376, pages 91-94.	
	C50	HSIAO, W. et al., "IslandPath: aiding detection of genomic islands in prokaryotes," Bioinformatics, 2003, 19, pages 418-420.	
	C51	HUECK, C.J., "Type III protein secretion systems in bacterial pathogens of animals and plants," Microbiol. Mol. Biol. Rev., 1998, 62, 379-433	
	C52	JARVIS, K.G. et al., "Secretion of extracellular proteins by enterohemorrhagic Escherichia coli via a putative type III secretion system," Infect. Immun., 1996, 64, pages 4826-4829.	
	C53	JOHNSON, M.S. et al., "A Structural Basis of Sequence Comparisons: An evaluation of scoring methodologies," Journal of Molecular Biology, 1993, 233, pages 716-738.	
	C54	KENNY, B. et al., "Co-ordinate regulation of distinct host cell signaling pathways by multifunctional enteropathogenic Escherichia coli effector molecules," Mol. Microbiol., 2002, 44, pages 1095-1107.	
	C55	KENNY, B. et al., "Enteropathogenic E. coli (EPEC) transfers its receptor for intimate adherence into mammalian cells," Cell, 1997, 91, pages 511-520.	
	C56	KENNY, B. et al., "Targeting of an enteropathogenic Escherichia coli (EPEC) effector protein to host mitochondria," Cell Microbiol., 2000, 2, pages 579-590.	
	C57	KNODLER, L.A. et al., "Salmonella effectors within a single pathogenicity island are differentially expressed and translocated by separate type III secretion systems," Mol. Microbiol., 2002, 43, pages 1089-1103.	
	C58	KNODLER, L.A. et al., "Salmonella type III effectors PipB and PipB2 are targeted to detergent-resistant microdomains on internal host cell membranes," Mol. Microbiol., 2003, 49, pages 685-704.	
	C59	KOHLER, G. et al., "Continuous cultures of fused cells secreting antibody of predefined specificity", Nature, 1975, 256(5517), pages 495-497.	
	C60	KOHLER, G. et al., "Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion", Eur. J. Immunol., 1976, 6(7), pages 511-519.	
	C61	KOHLER, G. et al., "Fusion between immunoglobulin-secreting and nonsecreting myeloma cell lines", Eur. J. Immunol., 1976, 6(4), pages 292-295.	
	C62	KRESSE, A.U. et al., "Characterization of SepL of Enterohemorrhagic Escherichia coli," J of Bacteriology, November 2000, 182(22), pages 6490-6498.	
	C63	KYTE, J. et al., "A simple method for displaying the hydropathic character of a protein", J. Mol. Biol., 1982, 157(1), pages 105-132.	
	C64	LARSSON, A. et al., "Chicken antibodies: taking advantage of evolution – a review," Poult Sci., 1993, 72(10), pages 1807-1812.	
	C65	LEE, N.S. et al., "Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Sheet

6 of 9

<b>Complete if Known</b>	
<b>Application No.</b>	10/577,742
<b>Filing Date</b>	July 19, 2006
<b>First Named Inventor</b>	Brett B. Finlay
<b>Art Unit</b>	1645
<b>Examiner Name</b>	Oluwatosin A. Ogunbiyi
<b>Attorney Docket Number</b>	27112-14589

**OTHER REFERENCES – NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>6</sup>
		cells", Nature Biotechnol., 2002, 20(5), pages 500-505.	
	C66	LEVINE, M.M. et al., "Escherichia coli strains that cause diarrhoea but do not produce heat-labile or heat-stable enterotoxins and are non-invasive," Lancet, 1978, 1, pages 1119-1122.	
	C67	LI, Y. et al., "Human response to Escherichia coli O157:H7 Infection: Antibodies to Secreted Virulence Factors," Infection and Immunity, September 2000, 68(9), Pages 5090-5095.	
	C68	LIMPENS, J. and Scheper, RJ, "Synergistic effects of locally administered cytostatic drugs and a surfactant on the development of delayed-type hypersensitivity to keyhole limpet haemocyanin in mice", Clin. Exp. Immunol., 1989, 78(2), pages 256-262.	
	C69	MARCHES, O. et al., "Enteropathogenic and enterohaemorrhagic Escherichia coli deliver a novel effector called Cif, which blocks cell cycle G2/M transition," Mol. Microbiol., December 2003, 50(5), pages 1553-1567.	
	C70	MARCHES, O. et al., "Role of tir and intimin in the virulence of rabbit enteropathogenic Escherichia coli serotype O103:H2", Infect. Immun., 2000, 68(4), pages 2171-2182.	
	C71	MCNAMARA, B.P. et al., "Translocated EspF protein from enteropathogenic Escherichia coli disrupts host intestinal barrier function," J. Clin. Invest., 2001, 107, pages 621-629.	
	C72	MELLIES, J.L. et al., "Identification of CesT, a chaperone for the type III secretion of Tir in enteropathogenic Escherichia coli", Mol. Microbiol., 1999, 33(6), pages 1176-1189.	
	C73	MILLER, S.I. et al., "A two-component regulatory system (phoP phoQ) controls Salmonella typhimurium virulence", Proc. Natl. Acad. Sci. USA, 1989, 86(13), pages 5054-5058.	
	C74	MIYAGISHI, M. et al., "U6 promoter-driven siRNAs with four uridine 3' overhangs efficiently suppress targeted gene expression in mammalian cells", Nature Biotechnol., 2002, 20(5), pages 497-500.	
	C75	MUNDY, R. et al., "Identification of a Novel Citrobacter rodentium Type III Secreted Protein, EspI, and Roles of this and Other Secreted Proteins in Infection," Infect. Immun., April 2004, 72(4), pages 2288-2302.	
	C76	MYERS, E.W. et al., "Optimal alignments in linear space", CABIOS, 1988, 4(1), pages 11-17.	
	C77	NATARO, J.P. et al., "Diarrheagenic Escherichia coli," Clin Microbiol. Rev., 1998, 11, pages 142-201.	
	C78	NAYLOR, S.W. et al., "Lymphoid follicle-desne mucosa at the terminal rectum is the prinispal site of colonization of enterhemorrhagic Escherichia coli O157:H7 in the bovine host," Infect. Immun., 2003, 71, pages 1505-1512.	
	C79	O'FARRELLY, C. et al., "Oral ingestion of egg yolk immunoglobulin from hens immunized with an enterotoxigenic Escherichia coli strain prevents diarrhea in rabbits challenged with the same strain," Infect. Immun., 1992, 60(7), pages 2593-2597.	
	C80	PADDISON, P.J. et al., "Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells", Genes & Dev., 2002, 16(8), pages 948-958.	
	C81	PAUL, C.P. et al., "Effective expression of small interfering RNA in human cells", Nature Biotechnol., 2002,	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Sheet

7 of 9

<b>Complete if Known</b>	
<b>Application No.</b>	10/577,742
<b>Filing Date</b>	July 19, 2006
<b>First Named Inventor</b>	Brett B. Finlay
<b>Art Unit</b>	1645
<b>Examiner Name</b>	Oluwatosin A. Ogunbiyi
<b>Attorney Docket Number</b>	27112-14589

**OTHER REFERENCES – NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>6</sup>
		20(5), pages 505-508.	
	C82	PEETERS, J.E. et al., "Biotype, serotype, and pathogenicity of attaching and effacing enteropathogenic Escherichia coli strains isolated from diarrheic commercial rabbits," Infect. Immun., 1988, 56, pages 1442-1448.	
	C83	PERNA, N.T. et al., "Genome Sequence of enterohaemorrhagic Escherichia coli O157:H7," Nature, 2001, 409, pages 529-533.	
	C84	PERNA, N.T. et al., "Molecular evolution of a pathogenicity island from enterohemorrhagic Escherichia coli O157:H7," Infect. Immun., 1998, 66, pages 3810-3817.	
	C85	PETNICKI-OCWIEJA, T. et al., "Genomewide identification of proteins secreted by the Hrp type III protein secretion system of <i>Pseudomonas syringae</i> pv. <i>tomato</i> DC3000", Proc. Natl. Acad. Sci. USA, 2002, 99(11), pages 7652-7657.	
	C86	PUENTE, J.L. et al., "The bundle-forming pili of enteropathogenic Escherichia coli: transcriptional regulation by environmental signals", Mol. Microbiol., 1996, 20(1), pages 87-100.	
	C87	ROMITO, M. et al., "Eliciting antigen-specific egg-yolk IgY with naked DNA," Biotechniques, 2001, 31(3), pages 670,672,674-675.	
	C88	SCHAUER, D.B. et al., "The eae gene of <i>Ctrobacter freudii</i> biotype 4280 is necessary for colonization in transmissible murine colonic hyperplasia," Infect. Immun., 1993, 61, pages 4654-4661.	
	C89	SCHIJNS, V.E. et al., "Immunological concepts of vaccine adjuvant activity", Curr. Op. Immunol., 2000, 12(4), pages 456-463.	
	C90	SHARP, P.A., "RNA interference—2001", Genes Dev., 2001, 15(5), pages 485-490.	
	C91	SMITH, R.H. et al., "Cyclophosphamide and dimethyl dioctadecyl ammonium bromide immunopotentiate the delayed-type hypersensitivity response to inactivated enveloped viruses, Immunology, 1986, 58(2), pages 245-250.	
	C92	SNIPPE, H. et al., "Adjuvanticity of dimethyl dioctadecyl ammonium bromide in guinea pigs. I. Skin test reactions", Int. Arch. Allergy Appl. Immunol., 1982, 68(3), pages 201-208.	
	C93	SPERANDIO, V. et al., "Quorum sensing controls expression of the type III secretion gene transcription and protein secretion in enterohemorrhagic and enteropathogenic Escherichia coli", Proc. Natl. Acad. Sci. USA, 1999, 96(26), pages 15196-15201.	
	C94	STATES, D.J. et al., "Improved Sensitivity of Nucleic Acid Database Search Using Application-Specific Scoring Matrices," Methods: A Companion to Methods in Enzymology, 1991, 3(1), pages 66-77.	
	C95	TAUSCHEK, M. et al., "Characterization and evidence of mobilization of the LEE pathogenicity island of rabbit-specific strains of enteropathogenic Escherichia coli," Mol. Microbiol., 2002, 44, pages 1533-1550.	
	C96	TU, X. et al., "EspH, a new cytoskeleton-modulating effector of enterohaemorrhagic and enteropathogenic Escherichia coli," Mol. Microbiol., 2003, 47, pages 595-606.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Sheet

8 of 9

<b>Complete if Known</b>	
<b>Application No.</b>	10/577,742
<b>Filing Date</b>	July 19, 2006
<b>First Named Inventor</b>	Brett B. Finlay
<b>Art Unit</b>	1645
<b>Examiner Name</b>	Oluwatosin A. Ogunbiyi
<b>Attorney Docket Number</b>	27112-14589

**OTHER REFERENCES – NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>6</sup>
	C97	VALLANCE, B.A. et al., "Host susceptibility to the attaching and effacing bacterial pathogen <i>Citrobacter rodentium</i> ," <i>Infect. Immun.</i> , 2003, 71, pages 3443-3453.	
	C98	VALLANCE, B.A. et al., "Mice lacking T and B lymphocytes develop transient colitis and crypt hyperplasia yet suffer impaired bacterial clearance during <i>Citrobacter rodentium</i> infection," <i>Infect. Immun.</i> , 2002, 70, pages 2070-2081.	
	C99	VALLANCE, B.A. et al., "Modulation of inducible nitric oxide synthase expression by the attaching and effacing bacterial pathogen <i>Citrobacter rodentium</i> in infected mice," <i>Infect. Immun.</i> , 2002, 70, pages 6424-6435.	
	C100	VAN DONKERSGOED, J. et al., "Environmental sources and transmission of <i>Escherichia coli</i> O157 in feedlot cattle", <i>Can Vet. J.</i> , 2001, 42(9), pages 714-720.	
	C101	VAN DONKERSGOED, J. et al., "The prevalence of verotoxins, <i>Escherichia coli</i> O157:H7, and <i>Salmonella</i> in the feces and rumen of cattle at processing", <i>Can Vet. J.</i> , 1999, 40(5), pages 332-338.	
	C102	VAUGHAN, T.J. et al., "Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library", <i>Nature Biotech.</i> , 1996, 14(3), pages 309-314.	
	C103	YOKOYAMA, H. et al., "Oral passive immunization against experimental salmonellosis in mice using chicken egg yolk antibodies specific for <i>Salmonella enteritidis</i> and <i>S. typhimurium</i> ," <i>Vaccine</i> , 1998, 16(4), pages 388-393.	
	C104	YOSHIDA, S. et al., "Shigella deliver an effector protein to trigger host microtubule destabilization, which promotes Rac1 activity and efficient bacterial internalization," <i>Embo J.</i> , 2002, 21, pages 2923-2935.	
	C105	YU, J.Y. et al., "RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells", <i>Proc. Natl. Acad. Sci. USA</i> , 2002, 99(9), pages 6047-6052.	
	C106	ZHU, C. et al., "Complete nucleotide sequence and analysis of the locus of enterocyte Effacement from rabbit diarrheagenic <i>Escherichia coli</i> RDEC-1," <i>Infect Immun.</i> , 2001, 69, pages 2107-2115.	
	C107	ZIEGLER, Z., "Ion traps come of age", <i>Anal. Chem.</i> , 2002, 74(17), pages 489A-492A.	
	C108	ZIOLA, B. et al., "In vitro proliferation of lymphocytes from cyclophosphamide-pretreated mice immunized with antigen mixed with dimethyl dioctadecyl ammonium bromide", <i>J. Immunol. Methods</i> , 1987, 97(2), pages 159-164.	
	C109	Hypothetical protein Z6024 UniProt/TrEMBL, database 1 March 2002 accession number Q8XAJ5.	
	C110	SUI, G., et al., "A DNA vector-based RNAi technology to suppress gene expression in mammalian cells," <i>PNAS</i> , April 16, 2002, Pages 5515-5520, Vol. 99, No. 8.	
	C111	KARLIN, S., et al., "Methods for assessing the statistical significance of molecular sequence features by using general scoring schemes," <i>PNAS</i> , March 1990, Pages 2264-2268, Vol. 87.	
	C112	HOPP, T., et al., "Prediction of protein antigenic determinants from amino acid sequences," <i>PNAS</i> , June 1981, Pages 3824-3828, Vol. 78, No. 6.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Sheet

9

of

9

<b>Complete if Known</b>	
<b>Application No.</b>	10/577,742
<b>Filing Date</b>	July 19, 2006
<b>First Named Inventor</b>	Brett B. Finlay
<b>Art Unit</b>	1645
<b>Examiner Name</b>	Oluwatosin A. Ogunbiyi
<b>Attorney Docket Number</b>	27112-14589

**OTHER REFERENCES – NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>6</sup>
	C113	GEYSEN, H., et al., "A Priori Delineation of a Peptide which Mimics a Discontinuous Antigenic Determinant," Molecular Immunology, 1986, Pages 709-715, Vol. 23, No. 23.	
	C114	GEYSEN, H., et al., "Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid," PNAS, July 1984, Pages 3998-4002, Vol. 81.	
	C115	CAPLEN, N., et al., "Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems," PNAS, August 14, 2001, Pages 9742-9747, Vol. 98, No. 17.	
	C116	BRUMMELKAMP, T., et al., "A System for Stable Expression of Short Interfering RNAs in Mammalian Cells," Science, April 19, 2002, Vol. 296.	
	C117	Escherichia coli, Accession Number AF071034, NCBI Sequence Viewer, August 13, 1998, 24 pages.	
	C118	Escherichia coli, Accession Number AE005174, NCBI Sequence Viewer, January 27, 2005, 3 pages.	
	C119	Escherichia coli, Accession Number NC002655, NCBI Sequence Viewer, July 19, 2006, 2005, 2 pages.	
	C120	Escherichia coli, Accession Number NC002695, NCBI Sequence Viewer, May 23, 2006, 2 pages.	
	C121	Escherichia coli, Accession Number AE005594, NCBI Sequence Viewer, March 21, 2001, 9 pages.	
	C122	Escherichia coli, Accession Number AE005595, NCBI Sequence Viewer, March 21, 2001, 7 pages.	
	C123	Escherichia coli, Accession Number AP002566, NCBI Sequence Viewer, March 20, 2004, 158 pages.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.